



The Impact of Ben's Run

Dec. 8, 2021 | Catherine Bollard, MD, MBChB, Director, Center for Cancer and Immunology



**Ben's Run 2021 raised
\$231,500**



 Children's National.

\$1,095,000 RAISED
since 2011




11 YEARS OF IMPACT

Opened and **supported 4 clinical trials** :

RESOLVE REST ATTACK TONI

Helped improve outcomes after BMT for children with high-risk leukemia

Helped **develop a FLT imaging protocol** and helped in the development of new blood tests to **detect leukemia relapse early**



Through the RESOLVE trial, helped support a **new treatment using cancer-killing T cells** to treat children with relapsed leukemia after BMT

Gave **over 60 patients** with cancer access to cutting-edge therapies and families hope



11 YEARS OF IMPACT

Thanks to the support from Ben's Run our team has leveraged **over \$2.5 Million in additional external funding:**

- Dr. Kirsten Williams received the Leukemia & Lymphoma Society (LLS) Translational Research Program (TRP) Award **(\$600K)**
- Drs. Mike Keller & Catherine Bollard were also awarded the TRP LLS Award for their work with the TONI trial **(\$600K)**
- Dr. Bollard received a Research Program Project (PO1) grant from the National Institutes of Health **(\$1M)** for Phase 2 of RESOLVE trial
- Dr. Amy Hont was the Recipient of Department of Defense (DOD) Career Development Award for her work with the REST and ATTACK trials **(\$500K)**
- Dr. Hannah Kinoshita's presentation on the RESOLVE trial was awarded an Abstract Achievement Award for her presentation at the 2021 American Society of Hematology Meeting.



IMPACT OVER THE LAST YEAR

Cell Therapy to Kill COVID-19

Training T cells to attack SARS-CoV-2, the virus that causes COVID-19

Continue with RESOLVE

With T cell therapy, most children with high-risk or relapsed AML are remaining in remission after BMT.

REST Trial

First in-human trial that demonstrates the promise of T cell therapy for recurrent or treatment resistant solid tumors



LOOKING AT THE YEAR AHEAD

- New funding will allow us to expand access to **10 new patients** at high risk of relapse
- Develop T cells as an “off the shelf” treatment to allow all children with cancer to have **easy and rapid access** to these novel therapies
- Begin the readily available protocol for **12 patients** for whom BMT is not an option
- Test whether children who receive SARS-Cov2 T cell therapies after BMT are immune to the virus that causes COVID-19

RECOGNIZING BEN'S LEGACY

“Ben’s Run” Nursing Station to be named within Center for Cancer and Blood Disorders



Thank You!

